Diarylheptanoid 35d overcomes EGFR TKI resistance by inducing hsp70-mediated lysosomal degradation of EGFR in EGFR-mutant lung adenocarcinoma

Epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma (LUAD) patients often respond to EGFR tyrosine kinase inhibitors (TKIs) initially but eventually develop resistance to TKIs. The switch of EGFR downstream signaling from TKI-sensitive to TKI-insensitive is a critical mechanism-drivin...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Xuan, Hsieh, Min-Tsang, Tseng, Tzu-Yu, Lin, Hui-Yi, Chang, Hung-Chih, Yau, Sir-Theng, Cheng, Wei-Chung, Ke, Baozhen, Liao, Hsiao-Hui, Wu, Chih-Ying, Liu, An-An, Wu, Meei-Maan, Huang, Kuo-Yen, Yang, Pan-Chyr, Kuo, Sheng-Chu, Hung, Mien-Chie, Lee, Pei-Chih
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Biochemistry and Molecular Biology 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10276293/
https://www.ncbi.nlm.nih.gov/pubmed/37178919
http://dx.doi.org/10.1016/j.jbc.2023.104814

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10276293/
https://www.ncbi.nlm.nih.gov/pubmed/37178919
http://dx.doi.org/10.1016/j.jbc.2023.104814

Ejemplares similares